IL-10对实验性肝纤维化大鼠转化生长因子β1表达的影响

目的探讨TGFβ1在实验性肝纤维化过程中的表达状况及IL-10对肝纤维化大鼠转化生长因子β1(TGFβ1)表达的影响.方法建立大鼠肝纤维化模型并行IL-10干预实验.从正常对照组(C组)和CCl4诱导肝纤维化模型组(M组)及IL-10干预肝纤维化组(T组)中取肝脏组织,采用S-P免疫组织化学方法检测分析不同组大鼠在肝纤维化进程的不同阶段肝组织中TGFβ1表达的情况.结果成功建立大鼠肝纤维化模型;随着肝纤维化程度的加重,TGFβ1在肝组织中阳性表达明显增强;经Ridit分析,C组与M组间TGFβ1阳性表达水平有显著性差异(P＜0.01);T组TGFβ1阳性表达较M组明显减弱,经Ridit分析,组间差异有显著性(P＜0.01).结论TGFβ1的阳性表达随着肝纤维化程度的进展升高,外源性IL-10对CCl4诱导的肝纤维化中TGFβ1的表达具有明显拮抗作用.     

IL-10对实验性肝纤维化大鼠血小板衍生生长因子-AA、BB表达的影响

目的:探讨IL-10干预对肝纤维化大鼠表达血小板衍生生长因子-AA、BB(PDGF-AA、BB)的影响。方法:建立大鼠肝纤维化模型并行IL-10干预。分批从对照组(C组)和CCl_4诱导肝纤维化模型组(M组)及IL-10干预肝纤维化组(T组)中取肝脏组织,采用S-P免疫组织化学方法检测分析PDGF-AA、BB在肝纤维化进程中的表达状况和IL-10干预后不同组大鼠及同组不同阶段大鼠肝组织中的表达结果。结果:成功建立大鼠肝纤维化模型小组肝组织中PDGF-AA、BB阳性表达明显增强,且PDGF-BB阳性表达强度高于PDGF-AA。经Ridit分析,两者在C组与M组间比较阳性表达均有显著性差异(P<0.01);T组与M组间比较PDGF-AA无统计学差异,但T组的PDGF-BB较M组明显减弱;PDGF-BB在肝纤维化组与IL-10干预组不同阶段阳性表达差异均有显著性。结论:PDGF-BB阳性强度随肝纤维化进展表达增强,而抑制PDGF-BB的表达可能是外源性IL-10拮抗肝纤维化的机制之一。     

IGF-1在肝纤维化大鼠中的表达及IL-10的干预作用

目的：探讨胰岛素样生长因子-l(IGF-1)在实验性大鼠肝纤维化过程中的表达状况及白细胞介素—10(IL-10)对肝纤维化大鼠IGF—l表达的影响。方法：建立大鼠肝纤维化模型并行IL-l0干预实验。分批从肝纤维化进程中不同阶段的对照组、CCl4诱导肝纤维化模型组及IL-l0干预肝纤维化组的大鼠中取肝脏组织，采用S—P免疫组织化学方法分别检测分析不同组及同组不同阶段大鼠肝组织中IGF-l的表达状况。结果：经CCl4诱导成功建立大鼠肝纤维化模型。随着肝纤维化程度的进展，IGF-l在肝组织中阳性表达明显增强；经Ridit分析，对照组(38．1％)与肝硬化模型组(92．0％)组间比较IGF-l阳性表达均有显著性差弄(P＜0．01)；IL-l0干预肝纤维化组IGF-l阳性表达(71．4％)较肝纤维化模型组均明显减弱，经Ridit分析组间均有显著性差异(P＜0．05)，且随IL-l0干预时间的延长，IGF—l在肝组织中阳性表达均逐渐减弱。结论：IGF-l随着肝纤维化程度的进展阳性表达增强，外源性IL-l0可降低CCl4诱导大鼠肝纤维化中IGF-l的表达。     

实验性肝纤维化大鼠细胞因子及超微结构的变化和意义

目的:研究四氯化碳(CCl4)诱导肝纤维化大鼠肝脏转化生长因子β1(TGFβ1)和结缔组织生长因子(CTGF)的表达及定位,血清IL-6、IL-10和IL-18的变化,以及肝组织超微结构的改变.方法:将28只大鼠随机分为正常对照组与模型组,模型组大鼠予以40?l4皮下注射8周后处死.免疫组化技术检测TGFβ1和CTGF在肝脏的表达及细胞内的定位;ELISA检测血清IL-6、IL-10和IL-18;电镜检测肝组织超微变化.结果:与正常组大鼠比较,模型组大鼠肝内TGFβ1和CTGF表达增加,免疫阳性反应信号的主要位于纤维间隔中的细胞浆;模型组大鼠血清IL-6和IL-18升高,而IL-10较正常组降低(P＜0.05 or P＜0.01);超微结构符合肝纤维化改变.结论:TGFβ1、CTGF、IL-6、IL-10和IL-18与肝纤维化的形成发展有关,可作为抗肝纤维化的新途径.     

PTEN在CCl_4诱导肝纤维化大鼠模型中的作用及益气活血方对其的影响

目的探讨第10号染色体缺失性磷酸酶张力蛋白同原物基因(PTEN)在CCl_4诱导肝纤维化大鼠模型中的作用,阐明益气活血方调节PTEN阻止肝纤维化的分子机制。方法选用27只Wistar雄性大鼠,随机分为3组,每组9只。其中肝纤维化组以CCl_4诱导建立肝纤维化模型;益气活血方组在CCl_4造模同时自拟以黄芪、丹参、云苓等中药为主的益气活血方进行干预实验;对照组以橄榄油腹腔注射。HE染色、Masson染色及胶原(Col1A1和Col4)免疫组化染色观察不同组别大鼠肝纤维化及胶原沉积程度;qRT-PCR、免疫组化及Western Blot检测TGFβ1、PTEN及其下游基因AKT、mTOR及p70S6K表达。计量资料多组间比较采用单因素方差分析,进一步两两比较采用LSD-t检验。结果肝纤维化组大鼠肝组织病理学可见窦周纤维化、汇管区纤维组织增生及胶原沉积、纤维间隔形成,伴随促肝纤维化基因TGFβ1 mRNA及蛋白表达上调,PTEN表达下调,而PTEN下游信号因子AKT、mTOR、p70S6K mRNA及磷酸化蛋白表达上调,与对照组比较差异均有统计学意义(P值均0.01)。应用益气活血方组大鼠肝纤维化显著改善,PTEN表达较肝纤维化组明显增加(P0.01),TGFβ1 mRNA及蛋白表达明显抑制(P值均0.05),AKT、mTOR及p70S6K的mRNA及磷酸化蛋白表达较肝纤维化组明显减少(P值均0.05)。结论益气活血方可能通过调节PTEN及其下游信号因子的表达,阻止及逆转肝纤维化。     

IL-10对实验性肝纤维化大鼠基质金属蛋白酶-2影响的研究

目的研究IL-10对实验性肝纤维化大鼠基质金属蛋白酶-2(MMP-2)的影响.方法建立大鼠肝纤维化模型并行IL-10干预实验,从正常大鼠(N组)和CCl4诱导肝纤维化大鼠(C组)及IL-10干预肝纤维化大鼠(E组)中取肝脏组织,采用S-P免疫组织化学方法检测分析不同组大鼠肝脏组织中MMP-2的表达状况.结果N组MMP-2阳性染色偶见于窦内皮细胞及肝细胞的胞浆;C组MMP-2阳性染色多见于汇管区新生的胆管细胞及纤维隔内条索状的成纤维细胞,26例标本中阳性13例,强阳性8例.第5周开始MMP-2有阳性表达,第9周阳性表达明显增强;E组MMP-2阳性染色明显减少,多见于汇管区的新生胆管细胞,27例标本中阳性10例,强阳性1例.Redit分析表明3组间MMP-2阳性表达有显著性差异(P＜0.01).结论MMP-2随着大鼠肝纤维化进展阳性表达升高,IL-10对CCl4诱导的大鼠肝纤维化具有保护作用,可明显抑制纤维化的生成和沉积.     

IL-10对TGF-β1诱导的大鼠肝星状细胞CTGF表达的影响

目的:探讨IL-10对大鼠肝星状细胞(hepaticstellate cells,HSC)表达CTGF的影响及其抗纤维化的可能机制.方法:体外培养大鼠肝星状细胞系rHSC-99,分别用不同浓度的IL-10、TGF-β1干预和两者共同干预48 h后,采用半定量RT-PCR法检测各组肝星状细胞中CTGF mRNA表达水平.结果:TGF-β1单独干预HSC,CTGF mRNA表达水平与对照组比较均明显增强(P<0.05);不同浓度的IL-10单独干预HSC,各目的基因表达与对照组比较无明显统计学意义;不同浓度的IL-10与TGFβ1共同干预HSC,CTGFmRNA表达水平与TGF-β1组比较均明显降低(P<0.05).结论:IL-10可显著抑制由TGF-β1诱导的CTGF mRNA的表达,这可能是其抗纤维化的机制之一.     

中药肝炎平对CCl4诱导的肝纤维化大鼠TGFβ1/Smad信号通路的影响

目的:研究中药肝炎平对CCl4诱导的大鼠肝纤维化肝脏TGFβ1及其受体TβR Ⅰ,TβR Ⅱ水平和 Smad3,Smad7及前胶原α2(Ⅰ)(Colla2)mRNA 表达的影响,探讨其抗纤维化的作用机制．方法:健康Wistar大鼠38R随机分为正常对照组(N组)、模型对照组(A组)以及肝炎平治疗组(B组)．N组每日以生理盐水10μL/g灌胃,A 组及B组用CCl4制备大鼠肝纤维化模型,B组 4wk后开始以肝炎平10μL/g灌胃给药,A组同时以生理盐水10μL／g灌胃,每日1次．9 wk 后处死大鼠,取肝组织作病理学检查,免疫组化检测TGFβ1及其受体TβR Ⅰ,TβR Ⅱ的表达, RT-PCR检测胞内信号蛋白Smad3,Smad7以及 Coila2 mRNA的表达．结果:与正常对照组相比,模型组TGFβ1、 TβR Ⅰ、TβRⅡ、Smad3、Colla2表达明显增强,Smad7表达明显下降．经肝炎平治疗后大鼠肝脏TGFβ1及其受体TβR Ⅰ,TβR Ⅱ表达均比模型组减弱(TGFβ1:4．30±0．16 vs 4．18 ±0．17．P<0．05;TβR Ⅰ:4．35±0．14 vs 4．24± 0．10．P<0．05;TβRⅡ:4.37±0．11 vs 4．27±0．08． P<0．05)．肝炎平同时下调Smad3和Colla2 mRNA的表达(Smad3:0．93±0．05 vs 0．90± 0．41．P<0．05;Colla2:0．95±0．03 vs 0．92±0．03． P<0．05),上调Smad7 mRNA的表达(0．84±0．05 vs 0．87±0．03,P<0．05)．另外,肝炎平组大鼠肝脏病理变化显著改善．结论:肝炎平对大鼠肝纤维化肝脏TGFβ1/ Smad信号通路有明显的影响,能抑制CCl4诱导的大鼠肝纤维化,其作用机制可能为抑制 TGFβ1．及其受体TβR Ⅰ,TβRⅡ蛋白表达,下调Smad3 mRNA,上调Smad7 mRNA的表达, 并最终下调了作为主要细胞外基质的Colla2 mRNA的表达．     

实验性大鼠肝纤维化TGFβ1及其受体mRNA与Smad3,7的表达

目的:研究四氯化碳(CCl4)诱导肝纤维化大鼠肝脏转化生长因子pl(TGFβ1)及其Ⅰ,Ⅱ型受体(TGFR)、Smad3、Smad7的定位及表达.方法:将24只大鼠随机分为正常对照组与模型组,模型组大鼠予以40%四氯化碳皮下注射8 wk后处死.RT-PCR检测肝组织TGFβ1,TGFR Ⅰ与TGFRⅡ;免疫组化技术检测TGFβ1,Smad3,Smad7在肝脏的表达及细胞内的定位;放射免疫方法检测透明质酸,肝组织病理检查.结果:与正常组大鼠比较,RT-PCR显示模型组大鼠肝内TGFβ1、TGFR Ⅰ与TGFRⅡmRNA表达明显增高;免疫组化结果显示TGFβ1与Smad3表达增加,而Smad7的表达降低,TGFβ1与Smad3的免疫阳性反应信号主要位于纤维间隔中的细胞质,Smad7主要在肝细胞质表达(正常组与模型组大鼠TGFβ1、Smad、Smad7平均光度分别0.61±0.33与1.57±0.53,0.248±0.042与0.785±0.904,4.674±1.143与0.470±0.097,P＜0.05);模型组大鼠血清透明质酸水平明显增高(正常组大鼠78.4±19.2 μg/L,模型组263.2±107.0 μg/L,P＜0.01),肝组织HE染色支持肝纤维化改变.结论:肝内TGFβ1,TGFR Ⅰ,TGFRⅡ,Smad3表达增强、Smad7表达减弱,提示TGFβ1及其受体与Smad信号通道蛋白参与了肝纤维化的发生发展,可作为防治肝纤维化发生发展的新途径之一.     

虫草多糖脂质体对肝纤维化大鼠转化生长因子β-基因表达的影响

目的：探讨冬虫夏草多糖脂质体(CPL)对肝纤维化大鼠肝组织转化生长因子(TGF)β-的影响。方法：动物分为3组,肝纤维化模型组、CPL治疗组和正常对照组,采用Northern杂交技术检测各组大鼠肝组织TGF-β基因的表达。结果：CPL治疗组大鼠肝脏中TGF-βmRNA表达量明显下降,与模型组大鼠比较差异有显著性(P&;lt;0.01)。结论：CPL可明显下调实验性肝纤维化大鼠肝组织TGF-β1mRNA的表达。     

Therapeutic effect of interleukin-10 on CCl4-induced hepatic fibrosis in rats

AIM: To study the therapeutic effect of exogenous interleukin-10 on CCl4-induced hepatic fibrosis in rats and its possible mechanisms. METHODS: Fourty-seven SD rats were randomly divided into control group (group N) and CCl4-induced hepatic fibrosis model group (group C). After CCl4 was given for 9 wk, the model group was divided into three groups. Rats in group M were put to death immediately,rats in group T were treated with IL-10 for another three wk and then put to death, rats in group R recovered after three weeks and were then killed. The degree of hepatic fibrosis was measured by HE staining and histological activity index (HAI). Histological activity index (HAI), change of collagen types I and III were measured by Picrosirius staining. The expression of TNF-alpha, MMP-2 and TIMP-1 in liver tissue was measured by S-P immunohistochemistry. RESULTS: CCl4- induced experimental rat hepatic fibrosis model was established successfully. The degree of hepatic fibrosis was markedly lower in group T than in groups M and R, and there was no difference between the two groups.The expression of collagen types I and III was significantly suppressed in group T and was slightly suppressed in groups M and R. The positive levels of TNF-alpha, MMP-2 and TIMP-1 in group M increased significantly compared to those in group N (P<0.01). The positive signals decreased significantly in groups T and R (P<0.01),but positive score was significantly lower in group T than in group R (P<0.01). CONCLUSION: Exogenous IL-10 can reverse CCl4-induced hepatic fibrosis in rats. IL-10 may exert its reversible effects on hepatic fibrosis by blocking CCl4-induced inflammation,inhibiting expression of MMP-2 and TIMP-1 and promoting resolution of collagen types I and III.     

Effects of interleukin-10 on activation and apoptosis of hepatic stellate cells in fibrotic rat liver

AIM:To study the effects of interleukin-10(IL-10)on the expression of α-smooth muscle actin(α-SMA),nuclear factor-κB(NF-κB)and Fas/Fas ligand(FasL)inhepatic stellate cells of experimental rats with hepaticfibrosis.METHODS:Sixty clean SD rats were randomly dividedinto control group(group N),liver fibrotic group(groupC)and IL-10 treatment group(group I).Control groupreceived intraperitoneal injection of saline(2ml·kg~(-1)),twicea week.Fibrotic group was injected intraperitoneallywith 50% carbon tetrachloride(CCl_4)(2 ml·kg~(-1)),twicea week.IL-10 treatment group was given IL-10 at adose of 4 μg·kg~(-1)20 minutes before CCl_4 administrationfrom the third week.Hepatic stellate cells(HSCs)wereisolated from these rats at the seventh and eleventhweeks during the course of liver fibrosis,respectively.The expression of α-SMA and NF-κB in HSCs wasmeasured by S-P immunohistochemistry.The expressionof Fas and FasL mRNA was measured by RT-PCR.Furthermore,liver tissues were harvested from threegroups at the same time.RESULTS:The CCl_4- induced experimental rat hepaticfibrosis model was established successfully.The purityof extracted hepatic stellate cells was about 95% andthe yield of hepatic stellate cells was 1.2-2.3×10~6/g livertissue averagely.The positive expression of α-SMA andNF-κB was 36.5% and 28.5% respectively in group N.The positive levels of α-SMA and NF-κB were increasedsignificantly in group C compared to group N(P<0.01).The positive signals decreased significantly(P<0.05)ingroup I.In the 11~(th)week,the HSCs of group I becameround with visible pyknotic nuclei.The expression ofNF-μB in group C was significantly increased in a time-dependentmanner(P<0.01),but there was no difference in the α-SMA expression(P>0.05).The mRNA of Fasand FasL in group C was significantly increased in a time-dependent manner compared to that in control group.After treated with IL-10,the expression level of Fas andFasL was higher in group I than in group C.CONCLUSION:The positive expression of α-SMA andNF-κB in hepatic stellate cells is decreased by ectogenicIL-10 in liver fibrosis induced by CCl_4.The expression ofFas and FasL is increased in the course of liver fibrosis,and is further increased by IL-10.IL-10 could inhibitthe activation of HSCs and cause apoptosis of activatedHSCs.     

Correlation between TIMP-1 expression and liver fibrosis in two rat liver fibrosis models

AIM: To evaluate serum TIMP-1 level and the correlation between TIMP-1 expression and liver fibrosis in immune-induced and CCL4-induced liver fibrosis models in rats. METHODS: Immune-induced and CCL4-induced liver fibrosis models were established by dexamethasone (0.01 mg) and CCL4 respectively. Serum TIMP-1 level was detected with ELISA, while histopathological grade of liver biopsy was evaluated. Spearman rank-correlation test was used to analyse the difference of the correlation between the TIMP-1 expression and hepatic fibrosis in the two fibrosis models. Furthermore, in situ hybridization was used to determine the expression difference of TIMP-1 mRNA in the two models. RESULTS: Positive correlation existed between serum TIMP-1 level of immune induced group and the histopathological stages of fibrosis liver of corresponding rats (Spearman rank-correlation test, rs= 0.812, P < 0.05), and the positive in situ hybridization signal of TIMP-1 mRNA was strong. In CCL4-induced liver fibrosis model, the correlation between the serum TIMP-1 level and the severity of hepatic fibrosis was not statistically significant(Spearman rank-correlation test, rs = 0.229, P > 0.05). And compared with immune-induced model, the positive in situ hybridization signal of TIMP-1 mRNA was weaker, while the expression variation was higher in hepatic fibrosis of the same severity. CONCLUSION: The correlations between TIMP-1 expression and liver fibrosis in two rat liver fibrosis models are different. In immune-induced model, serum TIMP-1 level could reflect the severity of liver fibrosis, while in CCL4-induced model, the correlation between the serum TIMP-1 level and the severity of hepatic fibrosis was not statistically significant.     

Antifibrotic effects of interleukin-10 on experimental hepatic fibrosis

BACKGROUND/AIMS: To study the effects of interleukin-10 on hepatic stellate cells and liver tissue in experimental rats hepatic fibrosis. METHODOLOGY: Rat hepatic fibrosis model induced by carbon tetrachloride was established. Liver tissues were harvested from the rats administered CCl4 with or without IL-10 treatment and the animals of the control group. The expression of TGF-beta1, MMP-2 and TIMP-1 in the liver tissues was measured by S-P immunohistochemistry. In addition, another model was established; HSCs in rats in each group were isolated. RT-PCR was employed to analyze TGF-beta1, MMP-2 and TIMP-1 mRNA expression in cells and immunocytochemistry was performed to detect protein expression of alpha-SMA, NF-kappaB, TGF-beta1, MMP-2 and TIMP-1 in HSCs. RESULTS: Rat hepatic fibrosis was developed successfully. The fibrosis changes were partially reversed by simultaneous administration of IL-10. The positive signals of TGF-beta1, MMP-2 and TIMP-1 were observed more frequently (P<0.05) in the CCl4-treated group compared to those in the IL-10-treated group and the control group. HSCs were successfully isolated. TGF-beta1, MMP-2 and TIMP-1 mRNA in HSCs increased obviously during the course of hepatic fibrosis, and their levels were decreased after the treatment with IL-10 (P<0.05). The immunocytochemistry positive levels for TGF-beta1, MMP-2, TIMP-1, alpha-SMA and NF-kappaB in the fibrogenesis group were increased significantly compared to the normal group (P<0.01). The positive signals decreased significantly (P<0.05) after the treatment with IL-10. CONCLUSIONS: The expression of TGF-beta1, MMP-2 and TIMP-1 increased in liver or in HSC of hepatic fibrosis rats and decreased after treatment with IL-10. The IL-10 could inhibit the activation of HSCs and make an antifibrogenic process come into effect in this way.     

Expression of insulin－like growth factor 1 and insulin－like growth factor 1 receptor and its intervention by interleukin－lO in experimental hepatic fibrosis

AIM: To study the expression of IGF-1 and IGF-1R and its intervention by interleukin-10 in the course of experimental hepatic fibrosis. METHODS: Hepatic fibrosis was induced in rats by carbon tetrachloride intoxication and liver specimens were taken from the rats administered CCl4 with or without IL-10 treatment and the animals of the control group. Immunoreactivities for insulin-like growth factor-1 (IGF-1) and IGF-1 receptor(IGF-1R) were demonstrated by immunohistochemistry, and their intensities were evaluated in different animal groups. RESULTS: The positive levels for IGF-1 and IGF-1R were increased with the development of hepatic fibrosis, with the positive signals localized in cytoplasm and/or at the plasmic membrane of hepatocytes. The positive signals of IGF-1 and IGF-1R were observed more frequently (P<0.01) in the CCl4-treated group (92.0 % and 90.0 %) compared to those in the control group. The positive signals decreased significantly (P<0.05) in IL-10-treated group. The responses in IGF-1 and IGF-1R expression correlated with the time of IL-10 treatment. CONCLUSION: The expression of IGF-1 and IGF-1R immunoreactivities in liver tissue seems to be up-regulated during development of hepatic fibrosis induced by CCl(4), and exogenic IL-10 inhibits the responses.     

恩替卡韦联合氧化苦参碱治疗对肝纤维化患者肝功能及肝纤维化指标的影响

目的:探讨恩替卡韦联合氧化苦参碱治疗对肝纤维化患者肝功能及肝纤维化指标的影响。方法:选取2018年1月至2019年12月在我院消化科住院的慢性乙型肝炎肝纤维化患者98例,分为联合治疗组和恩替卡韦组各49例,两组患者均进行常规治疗,恩替卡韦组患者口服恩替卡韦治疗,联合治疗组患者采用恩替卡韦联合氧化苦参碱治疗,观察两组患者治疗前后肝功能、肝纤维化、炎症指标的变化及不良反应发生情况。结果:与恩替卡韦组相比,联合治疗组患者肝功能、肝纤维化、炎症指标好转时间、IL-6、IL-8、IL-10、TGF-β1、IFN-γ、TNF-α、肝功能指标、肝纤维化指标水平明显降低(P<0.05);与恩替卡韦组相比,联合治疗组IL-2水平明显下降(P<0.05),治疗总有效率较高(P<0.05);两组患者不良反应发生情况无明显差异(P>0.05)。结论:应用恩替卡韦联合氧化苦参碱治疗肝纤维化患者,可有效改善肝功能及肝纤维化程度,效果显著。